Cystic fibrosis Trials in Seattle, United States
Conditions / Cystic fibrosis / Seattle, United States
Clinical trials for Cystic fibrosis investigate a range of treatment strategies and patient populations.
126 total trials for this combination
Showing top 10 of 126 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03525574 | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | COMPLETED | PHASE3 |
| NCT01180634 | MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis | COMPLETED | PHASE3 |
| NCT03525444 | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | COMPLETED | PHASE3 |
| NCT01270347 | Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients | COMPLETED | PHASE3 |
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05362344 | Colorectal Cancer Screening in Cystic Fibrosis | ACTIVE_NOT_RECRUITING | — |
| NCT02565914 | A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation | COMPLETED | PHASE3 |
| NCT05076149 | A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation | COMPLETED | PHASE3 |
| NCT02392234 | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation | COMPLETED | PHASE3 |
| NCT05033080 | A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) | COMPLETED | PHASE3 |